HDBNJ3049 / Handok, BNJ Biopharma - LARVOL DELTA

HDBNJ3049: A novel EGFR-targeting PROTAC to overcome C797S-mediated osimertinib resistance in NSCLC (AACR 2025) - "The lead candidate, HDBNJ3049, exhibited superior activity across all tested EGFR mutant cell lines, including potent growth inhibition of C797S-mutant Ba/F3, and H1975 cells (GI50 as low as 17 nM and 50 nM for L858R/T790M/C797S Ba/F3 and H1975, respectively), and robust degradation of Del19/T790M/C797S mutant EGFR (DC50: 13 nM, Dmax: 98%). In vivo pharmacokinetic and pharmacodynamic studies further validated the therapeutic potential of HDBNJ3049, establishing it as a highly promising lead candidate for overcoming osimertinib resistance in NSCLC and offering new hope for patients with limited treatment options."

Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • EGFR